They developed a sensitivity-tuned ADGRE2-CAR with a CLEC12A-targeted chimeric costimulatory receptor, which proved greater activity against LSCs without increasing toxicity against HSCs in vitro and in murine models, and they have started a phase I clinical trial evaluating this strategy in patients with R/R AML (NCT05748197). The gene discussed is CLEC12A; the disease is acute myeloid leukemia.